Research ExplorerPublicationsInterleukin-22 is frequently expressed in small- and large-c...

Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells

Standard

Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. / Kobold, Sebastian; Völk, Stefanie; Clauditz, Till; Küpper, Natascha Jennifer; Minner, Sarah; Tufman, Amanda; Düwell, Peter; Lindner, Michael; Koch, Ina; Heidegger, Simon; Rothenfuer, Simon; Schnurr, Max; Huber, Rudolf Maria; Wilczak, Waldemar; Endres, Stefan.

In: J THORAC ONCOL, Vol. 8, No. 8, 01.08.2013, p. 1032-42.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kobold, S, Völk, S, Clauditz, T, Küpper, NJ, Minner, S, Tufman, A, Düwell, P, Lindner, M, Koch, I, Heidegger, S, Rothenfuer, S, Schnurr, M, Huber, RM, Wilczak, W & Endres, S 2013, 'Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells', J THORAC ONCOL, vol. 8, no. 8, pp. 1032-42. https://doi.org/10.1097/JTO.0b013e31829923c8

APA

Kobold, S., Völk, S., Clauditz, T., Küpper, N. J., Minner, S., Tufman, A., Düwell, P., Lindner, M., Koch, I., Heidegger, S., Rothenfuer, S., Schnurr, M., Huber, R. M., Wilczak, W., & Endres, S. (2013). Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J THORAC ONCOL, 8(8), 1032-42. https://doi.org/10.1097/JTO.0b013e31829923c8

Vancouver

Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A et al. Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J THORAC ONCOL. 2013 Aug 1;8(8):1032-42. https://doi.org/10.1097/JTO.0b013e31829923c8

Bibtex

@article{f81ee4edb9c74cf9b65e256052a39af0,
title = "Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells",
abstract = "INTRODUCTION: In lung cancer, interleukin-22 (IL-22) expression within primary tissue has been demonstrated, but the frequency and the functional consequence of IL-22 signaling have not been addressed. This study aims at analyzing the cellular effects of IL-22 on lung carcinoma cell lines and the prognostic impact of IL-22 tissue expression in lung cancer patients.METHODS: Biological effects of IL-22 signaling were investigated in seven lung cancer cell lines by Western blot, flow cytometry, real-time polymerase chain reaction, and proliferation assays. Tumor tissue specimens of two cohorts with a total of 2300 lung cancer patients were tested for IL-22 expression by immunohistochemistry. IL-22 serum concentrations were analyzed in 103 additional patients by enzyme-linked immunosorbent assay.RESULTS: We found the IL-22 receptor 1 (IL-22-R1) to be expressed in six of seven lung cancer cell lines. However IL-22 signaling was functional in only four cell lines, where IL-22 induced signal transducer activator of transcription 3 phosphorylation and increased cell proliferation. Furthermore, IL-22 induced the expression of antiapoptotic B-cell lymphoma 2, but did not rescue tumor cells from carboplatin-induced apoptosis. Cisplatin-resistant cell lines showed a significant up-regulation of IL-22-R1 along with a stronger proliferative response to IL-22 stimulation. IL-22 was preferentially expressed in small- and large-cell lung carcinoma (58% and 46% of cases, respectively). However, no correlation between IL-22 expression by immunohistochemistry and prognosis was observed.CONCLUSION: IL-22 is frequently expressed in lung cancer tissue. Enhanced IL-22-R1 expression and signaling in chemotherapy-refractory cell lines are indicative of a protumorigenic function of IL-22 and may contribute to a more aggressive phenotype.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Large Cell, Cell Line, Tumor, Child, Drug Resistance, Neoplasm, Female, Humans, Immunohistochemistry, Interleukins, Lung Neoplasms, Male, Middle Aged, Prognosis, Receptors, Interleukin, Small Cell Lung Carcinoma",
author = "Sebastian Kobold and Stefanie V{\"o}lk and Till Clauditz and K{\"u}pper, {Natascha Jennifer} and Sarah Minner and Amanda Tufman and Peter D{\"u}well and Michael Lindner and Ina Koch and Simon Heidegger and Simon Rothenfuer and Max Schnurr and Huber, {Rudolf Maria} and Waldemar Wilczak and Stefan Endres",
year = "2013",
month = aug,
day = "1",
doi = "10.1097/JTO.0b013e31829923c8",
language = "English",
volume = "8",
pages = "1032--42",
journal = "J THORAC ONCOL",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",

}

RIS

TY - JOUR

T1 - Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells

AU - Kobold, Sebastian

AU - Völk, Stefanie

AU - Clauditz, Till

AU - Küpper, Natascha Jennifer

AU - Minner, Sarah

AU - Tufman, Amanda

AU - Düwell, Peter

AU - Lindner, Michael

AU - Koch, Ina

AU - Heidegger, Simon

AU - Rothenfuer, Simon

AU - Schnurr, Max

AU - Huber, Rudolf Maria

AU - Wilczak, Waldemar

AU - Endres, Stefan

PY - 2013/8/1

Y1 - 2013/8/1

N2 - INTRODUCTION: In lung cancer, interleukin-22 (IL-22) expression within primary tissue has been demonstrated, but the frequency and the functional consequence of IL-22 signaling have not been addressed. This study aims at analyzing the cellular effects of IL-22 on lung carcinoma cell lines and the prognostic impact of IL-22 tissue expression in lung cancer patients.METHODS: Biological effects of IL-22 signaling were investigated in seven lung cancer cell lines by Western blot, flow cytometry, real-time polymerase chain reaction, and proliferation assays. Tumor tissue specimens of two cohorts with a total of 2300 lung cancer patients were tested for IL-22 expression by immunohistochemistry. IL-22 serum concentrations were analyzed in 103 additional patients by enzyme-linked immunosorbent assay.RESULTS: We found the IL-22 receptor 1 (IL-22-R1) to be expressed in six of seven lung cancer cell lines. However IL-22 signaling was functional in only four cell lines, where IL-22 induced signal transducer activator of transcription 3 phosphorylation and increased cell proliferation. Furthermore, IL-22 induced the expression of antiapoptotic B-cell lymphoma 2, but did not rescue tumor cells from carboplatin-induced apoptosis. Cisplatin-resistant cell lines showed a significant up-regulation of IL-22-R1 along with a stronger proliferative response to IL-22 stimulation. IL-22 was preferentially expressed in small- and large-cell lung carcinoma (58% and 46% of cases, respectively). However, no correlation between IL-22 expression by immunohistochemistry and prognosis was observed.CONCLUSION: IL-22 is frequently expressed in lung cancer tissue. Enhanced IL-22-R1 expression and signaling in chemotherapy-refractory cell lines are indicative of a protumorigenic function of IL-22 and may contribute to a more aggressive phenotype.

AB - INTRODUCTION: In lung cancer, interleukin-22 (IL-22) expression within primary tissue has been demonstrated, but the frequency and the functional consequence of IL-22 signaling have not been addressed. This study aims at analyzing the cellular effects of IL-22 on lung carcinoma cell lines and the prognostic impact of IL-22 tissue expression in lung cancer patients.METHODS: Biological effects of IL-22 signaling were investigated in seven lung cancer cell lines by Western blot, flow cytometry, real-time polymerase chain reaction, and proliferation assays. Tumor tissue specimens of two cohorts with a total of 2300 lung cancer patients were tested for IL-22 expression by immunohistochemistry. IL-22 serum concentrations were analyzed in 103 additional patients by enzyme-linked immunosorbent assay.RESULTS: We found the IL-22 receptor 1 (IL-22-R1) to be expressed in six of seven lung cancer cell lines. However IL-22 signaling was functional in only four cell lines, where IL-22 induced signal transducer activator of transcription 3 phosphorylation and increased cell proliferation. Furthermore, IL-22 induced the expression of antiapoptotic B-cell lymphoma 2, but did not rescue tumor cells from carboplatin-induced apoptosis. Cisplatin-resistant cell lines showed a significant up-regulation of IL-22-R1 along with a stronger proliferative response to IL-22 stimulation. IL-22 was preferentially expressed in small- and large-cell lung carcinoma (58% and 46% of cases, respectively). However, no correlation between IL-22 expression by immunohistochemistry and prognosis was observed.CONCLUSION: IL-22 is frequently expressed in lung cancer tissue. Enhanced IL-22-R1 expression and signaling in chemotherapy-refractory cell lines are indicative of a protumorigenic function of IL-22 and may contribute to a more aggressive phenotype.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Large Cell

KW - Cell Line, Tumor

KW - Child

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Interleukins

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Receptors, Interleukin

KW - Small Cell Lung Carcinoma

U2 - 10.1097/JTO.0b013e31829923c8

DO - 10.1097/JTO.0b013e31829923c8

M3 - SCORING: Journal article

C2 - 23774470

VL - 8

SP - 1032

EP - 1042

JO - J THORAC ONCOL

JF - J THORAC ONCOL

SN - 1556-0864

IS - 8

ER -